NCT01808326View on ClinicalTrials.gov

A Phase II, Open Label, Single Arm, Multicenter Study of Chlorambucil in Japanese Previously Untreated Patients With Chronic Lymphocytic Leukemia

PHASE2CompletedINTERVENTIONAL
Enrollment

5

Participants

Timeline

Start Date

April 30, 2013

Primary Completion Date

November 30, 2014

Study Completion Date

November 30, 2014

Conditions
Leukaemia, Lymphoblastic
Interventions
DRUG

chlorambucil, tablets

2mg tablets, chlorambucil dose: 10mg/m2 PO at days 1-7 every 28 days; duration: minimum of 3 cycles until best response or maximum of 12 cycles

Trial Locations (6)

466-8650

GSK Investigational Site, Aichi

811-1395

GSK Investigational Site, Fukuoka

373-8550

GSK Investigational Site, Gunma

980-8574

GSK Investigational Site, Miyagi

104-0045

GSK Investigational Site, Tokyo

135-8550

GSK Investigational Site, Tokyo

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT01808326 - A Phase II, Open Label, Single Arm, Multicenter Study of Chlorambucil in Japanese Previously Untreated Patients With Chronic Lymphocytic Leukemia | Biotech Hunter | Biotech Hunter